anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Participants in this group will consent to participate in a study about quality of life for patients with cancer seeking outpatient palliative care. They will be seen in a palliative care oncology clinic at which time they will be offered additional resources to promote symptom management. They will be asked to complete a series of surveys every two weeks for 16 weeks which will assess their quality of life, symptoms, and medication use.
A film 10 capable of emitting far-infrared rays comprises a surface layer 20 and a carbonic layer 30 coating the surface layer 20 and having carbon of at least 60wt%. Preferably, the carbonic layer 30 is made of at least one material selected from the group consisting of bamboo charcoal powders, carbon fibres, carbon nanotubes, activated carbon powders, activated carbon grains and activated carbon fibres. The carbonic layer 30 may be a fabric, nonwoven, a paper having vents or a membrane. The carbonic layer 30 may further comprise an artificial fibre of at most 40wt% or a metal of at most 2wt% in the shape of metallic particles or membrane wherein the metal is selected from the group including silver, gold, palladium, copper, zinc, aluminium and chromium. Preferably the surface layer 20 is made from natural fibre, artificial fibre, polymer, natural leather, artificial leather or a combination thereof. The film 10 may be useful in emitting far-infrared rays to heighten the temperature of human skin, increase blood circulation and enhance the absorbability of active ingredients to the skin. The film 10 may also be useful in protecting the skin against ultraviolet rays.
This trial is divided into the combined dose escalation (Phase Ib) and the expansion phase (Phase II), as follows:

1. In the phase Ib study, it is planned to include patients with advanced malignant tumors who have no standard treatment or who have failed the previous standard treatment or who do not apply standard treatment at this stage. According to the "rolling six design" dose escalation method, the tolerability of LBL-007 200 and 400 mg dose levels was evaluated. Each dose group included 3 to 6 subjects, and the total sample size for stage Ib was about 9-12 (specifically The sample size is subject to actual occurrence). The dosage regimen of LBL-007 is once every 3 weeks (Q3W), intravenous infusion; the dosage regimen of combination drug teriprizumab is 240 mg, once every 3 weeks (Q3W), intravenous Infusion. During the experiment, necessary adjustments can be made to the dosing frequency or incremental group settings based on the PK data and safety data obtained. In this study, every 3 weeks is a dosing cycle, and the DLT observation period is 3 weeks after the first dosing.
2. According to the LBL-007 global research and development data and the safety, tolerability and PK data of the phase Ib clinical study, the recommended dose of phase II clinical study (RP2D) was obtained for the expansion of target indications, including advanced esophageal squamous cell carcinoma, head Patients with malignant tumors such as cervical squamous cell carcinoma, cervical cancer, and nasopharyngeal carcinoma. During the screening period of this study, subjects need to undergo relevant inspections or observations, and those who meet the screening requirements will enter the treatment period. During the treatment period, all subjects will receive a certain dose of the test drug combined with teriprizumab until intolerable toxicity, disease progression, death, voluntary withdrawal, loss to follow-up, or continuous administration for 2 years ( Whichever occurs first). Subjects will be evaluated for anti-tumor efficacy according to the efficacy evaluation criteria for solid tumors (RECIST V1.1) and immunotherapy solid tumor efficacy evaluation criteria (iRECIST), once every 6 weeks after the first administration, and the frequency will be adjusted after 24 weeks It is once every 9 weeks. All subjects in this study will have a safety follow-up 30 days (+7 days) after the last administration or before starting a new anti-tumor therapy, and then enter the survival follow-up, and will collect whether to accept new anti-tumor therapy and survival information, etc. , Until the subject's death or loss to follow-up or withdrawal of informed consent. In this trial, all subjects in phase Ib/II underwent a sparse blood sampling population PK study; all subjects collected blood samples for the evaluation of LBL-007 immunogenicity; all subjects collected tumor tissue samples for biomarkers For related explorations, some subjects will collect blood samples for explorations related to receptor occupancy.
1502563 Immunological Testing KABI AB 26 Jan 1976 [27 Jan 1975 ] 02936/76 Heading G1B A method of immunochemical quantification of an antigen comprises contacting a sample containing the antigen with a capillary containing, porous carrier to which antibodies have been bound and thence allowing capillary migration to occur and then assaying the antigen containing areas of the sample wetted device by adding antibodies bound to a colour indicator. The antibodies may be bound to the carrier by absorption, absorption or covalent bonding e.g. bonded covalently to the carrier via cyanogen bromide or glutaric aldehyde. The capillary containing porous material may be selected from cellulose fibre, starch, a 3 dimensional network as a matrix of dextran chains cross-linked with epichlorhydrin or a plastics or ceramic material; mixtures of carriers may be used. Suitable mixtures include a silica modified polymer in which finely divided silica is embedded in a continuous matrix which is e.g. pvc, vinyl chloride-propylene copolymer or vinyl chloridevinyl acetate copolymer. The colour indicator may be a fluorescent compound or an enzyme which catalyzes a colour developing reaction. Suitable colour indicators are fluoresceine-isothiocyanate, rhodamine or dansylchloride.
Patients will receive TMZ at a target dose of 150-200 mg/m\^2/d for 5 days every 4 (+2) weeks for up to 12 cycles. DC vaccines will be administered in equal amounts to both inguinal regions. DC vaccines #1-3 occur every 2 weeks and all subsequent vaccines (up to 10) occur monthly. Group 2 patients will receive a single dose of Td toxoid administered to a single side of the groin and saline administered to the contralateral side the day prior to the 4th DC vaccine, which is always given bilaterally at the groin site.
A left atrial parameter acquiring method is proposed. The left atrial parameter acquiring method includes an imaging acquiring step, a heart model establishing step, a center route calculating step, a cross section setting step and a left atrial parameter calculating step. The imaging acquiring step is performed to acquire a chest computed tomography (CT) image sequence. The heart model establishing step is performed to combine the chest CT scanning images into a three-dimensional heart model. The center route calculating step is performed to acquire a first coordinate corresponding to a fossa ovale and a second coordinate corresponding to a left atrial, and calculate a center route between the fossa ovale and the left atrial. The cross section setting step is performed to set a cross section. The cross section is corresponding to an opening of the left atrial. The left atrial parameter calculating step is performed to calculate a left atrial parameter. Thus, the left atrial parameter acquiring method of the present disclosure can calculate the left atrial parameter according to the three-dimensional heart model.
Approximately 3 patients will receive 6, bi-weekly, subcutaneous injections of a .4 mg dose of PVX-410 in combination with an intramuscular injection of Hiltonol (poly ICLC). Patients will complete a 12 week treatment phase and then will be followed for safety, immunogenicity and clinical response for 12 months.
The invention discloses a novel pharmacological effect and a molecular mechanism of salidroside. The inhibition function of the salidroside on UV induced photodermatoses such as sunburn and chronic actinic dermatitis is realized through binding with cyclooxygenase-2(COX-2), inhibition activity of cyclooxygenase-2(COX-2) and blockage of a COX-2 signal pathway. The immunopathogenesis prompts that expression of COX-2, P38 and JNK in skin lesions caused by photodermatoses is increased. The COX-2 activity affects phosphorylation of UV induced P38 and JNK in a cell experiment. The in-vitro protein binding experiment shows that the salidroside can be directly bound with COX-2 so as to inhibit COX-2 activation and inhibit phosphorylation of P38, JNK and H2AX and secretion of IL-6 and TNF-alpha. A cell experiment result is also verified by an animal experiment.
PURPOSE:To obtain a heat-resistant albumin protein having excellent solubility to clear water, etc., exhibiting heat resistance even in dissolving into a salt solution and suitable in a raw material for cosmetic or food, by linking an albumen protein with a surfactant. CONSTITUTION:An albumen protein is linked with a surfactant (preferably sodium laurylsulfate, etc.) to provide the aimed product. For example, using 30-100pts.wt. clear water and 0.1-10pts.wt. surfactant to 100pts.wt. albumen, the surfactant is dissolved in the clear water and the solution is then mixed with the albumen and further the mixture is stirred at 20-30 deg.C for 30-120min to carry out the bonding reaction.
The efficacy of TIBSOVO was evaluated in an open-label, single-arm, multicenter study (study AG120-C-001, NCT02074839) of 18 adult patients with relapsed or refractory MDS with an IDH1 mutation. IDH1 mutations were detected in peripheral blood or bone marrow by a local or central diagnostic test and confirmed retrospectively using the Abbott RealTime™ IDH1 Assay. TIBSOVO was given orally at a starting dose of 500 mg daily continuous for 28-day cycles until disease progression, development of unacceptable toxicity, or undergoing hematopoietic stem cell transplantation. One (6%) of the 18 patients went on to stem cell transplantation following TIBSOVO treatment. 

The baseline demographic and disease characteristics are shown in Table 19.

Efficacy was established on the basis of the rate of complete remission (CR) or partial remission (PR) as per the 2006 International Working Group response criteria for MDS, the duration of CR+PR, and the rate of conversion from transfusion dependence to transfusion independence. All observed responses were CRs. The efficacy results are shown in Table 20. The median follow-up was 27.1 months (range 3.7 to 88.7 months) and median duration of exposure to TIBSOVO was 8.3 months (range 3.3 to 78.8 months).

For patients who achieved a CR, the median time to CR was 1.9 months (range, 1.0 to 5.6 months).

Among the 9 patients who were dependent on red blood cell (RBC) and/or platelet transfusions at baseline, 6 (67%) became independent of RBC and platelet transfusions during any 56-day post-baseline period. Of the 9 patients who were independent of both RBC and platelet transfusions at baseline, 7 (78%) remained transfusion independent during any 56-day post-baseline period.
A tablet for the transmucosal administration of nicotine. The nicotine is in one or more layers upon a non-nicotine containing matrix. The nicotine layers rapidly dissolve in the mouth. The nicotine is then rapidly absorbed by the intra-oral mucosal surfaces. The short, rapid pulse of nicotine is similar to that given by cigarette smoking. The nicotine may be provided in a plurality of layers separated by one or more layers that are essentially free of nicotine to support the nicotine layers.
The present invention provides an adhesive sheet that is for attachment to skin, that adheres sufficiently to skin, and that causes little skin irritation. A first adhesive sheet for attachment to skin according to the present invention comprises an adhesive layer formed on a support body. The adhesive layer comprises no tackifiers and comprises at least a thermoplastic elastomer, a non-volatile hydrocarbon oil, and polyisobutylene having a viscosity-average molecular weight of more than 100,000 but no more than 500,000. A second adhesive sheet for attachment to skin according to the present invention comprises an adhesive layer formed on a support body. The adhesive layer comprises at least a thermoplastic elastomer, more than 120 parts by weight but no more than 800 parts by weight of a non-volatile hydrocarbon oil, and more than 3 parts by weight but no more than 500 parts by weight of polyisobutylene with respect to 100 parts by weight of the elastomer. The polyisobutylene comprises no tackifiers and is a mixture of low molecular weight polyisobutylene having a viscosity-average molecular weight of more than 30,000 but no more than 100,000 and high molecular weight polyisobutylene having a viscosity-average molecular weight of more than 500,000 but no more than 5,000,000. Also provided is a percutaneous absorption preparation containing a drug or a pharmaceutically acceptable salt thereof on the adhesive layer of the adhesive sheet for attachment to skin.
The anticancer composition containing synergist is one kind of slow releasing injection and slow releasing implant. The slow releasing injection consists of slow released microsphere comprising effective anticancer component and slow releasing supplementary material, and special solvent containing suspending agent. The suspending agent is selected from sodium carboxymethyl cellulose, etc, and has viscosity of 100cp-3000cp. The slow releasing implant consists of effective anticancer component and slow releasing supplementary material. The slow releasing supplementary material is selected from polylactic acid, polifeprosan, etc. The effective anticancer component is composition of anticancer medicine phosphoinositide-3-kinase inhibitor, pyridine analog, etc and the synergist rapamycin. The slow releasing injection and the slow releasing implant may be used alone to inhibit the growth of tumor or in conjunction with chemotherapy to raise the curative effect.
UNLABELLED: We report a deep next-generation sequencing analysis of 13 sequentially obtained tumor samples, eight sequentially obtained circulating tumor DNA (ctDNA) samples and three germline DNA samples over the life history of 3 patients with triple-negative breast cancer (TNBC), 2 of whom had germline pathogenic BRCA1 mutation, to unravel tumor evolution. Tumor tissue from all timepoints and germline DNA was subjected to whole-exome sequencing (WES), custom amplicon deep sequencing (30,000X) of a WES-derived somatic mutation panel, and SNP arrays for copy-number variation (CNV), while whole transcriptome sequencing (RNA-seq) was performed only on somatic tumor.There was enrichment of homologous recombination deficiency signature in all tumors and widespread CNV, which remained largely stable over time. Somatic tumor mutation numbers varied between patients and within each patient (range: 70-216, one outlier). There was minimal mutational overlap between patients with TP53 being the sole commonly mutated gene, but there was substantial overlap in sequential samples in each patient. Each patient's tumor contained a founding ("stem") clone at diagnosis, which persisted over time, from which all other clones ("subclone") were derived ("branching evolution"), which contained mutations in well-characterized cancer-related genes like PDGFRB, ARID2, TP53 (Patient_02), TP53, BRAF, BRIP1, CSF3R (Patient_04), and TP53, APC, EZH2 (Patient_07). Including stem and subclones, tumors from all patients were polyclonal at diagnosis and during disease progression. ctDNA recapitulated most tissue-derived stem clonal and subclonal mutations while detecting some additional subclonal mutations. RNA-seq revealed a stable basal-like pattern, with most highly expressed variants belonging to stem clone.
SIGNIFICANCE: In germline BRCA1 mutated and BRCA wild-type patients, TNBC shows a branching evolutionary pattern of mutations with a single founding clone, are polyclonal throughout their disease course, and have widespread copy-number aberrations. This evolutionary pattern may be associated with treatment resistance or sensitivity and could be therapeutically exploited.
The minimum effective dose of local anesthetics for spinal anesthesia using Taylor's approach is not known. This study aims to determine the minimum effective dose of bupivacaine 0.5% using a biased coin design up-and-down sequential method. Patients will receive real-time ultrasound guided spinal anesthesia using Taylor's approach. The initial dose is chosen as 15 mg on the basis of clinical experience. Subsequently, if a patient has an inadequate block, the bupivacaine dose is increased by 2 mg in the next subject. If a patient has a successful block, the next subject is randomized to receive either a lower dose (with a decrement of 2 mg), with a probability of b = 0.11, or the same dose, with a probability of 1 - b = 0.89. Forty five successful blocks will be accomplished. MED90 will be calculated by isotonic regression.
During the treatment period, subjects will also receive oral apatinib mesylate tablets, one tablet/dose (250 mg/tablet), once daily, continuously. Treatment will continue until an event occurs that meets the criteria for discontinuation of treatment.
Patients receive selumetinib PO BID for 3 weeks. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
Roux-en-y gastric bypass is performed with the patient in the French position by a bariatric surgeon with 8 years of experience. A single port was placed in the umbilicus, an additional trocar (5mm) was placed in the right side of the abdomen. The surgery is started by performing the liver retraction with the grasper plus magnet attached to the border for the correct visualization of the surgical field. Later, the division of the major curvature of the omentum is started, and as it is performed in a superior direction, the magnet is positioned to retract the fundus and finishing exposing the esophageal hiatus where a hiatal hernia is visualized, which is decided to be repaired transoperatively. For the hiatoplasty, after placing a reference around the stomach, the magnet is positioned in that reference to retract the stomach and esophagus and to be able to suture the hernia defect. Then we proceed to perform the RYGB with the simplified technique, starting with the reference attached to the magnet but this time at the opposite end to start the resection of the lesser omentum, a minor step prior to the confection of the pouch. The pouch confection is done with 3 blue cartridges. Continuing with the procedure, the retraction of the transverse colon is performed with the use of the magnet to visualize the treitz angle and start the 60 cm measurement of the biliopancreatic limb. Later, gastrojejunal anastomosis is performed traditionally. Once this step is finished, the 100 cm alimentary limb is measured and then, the magnet-assisted jejunal anastomosis is performed. The Petersen defect and the intermesenteric defect is closed assisted by magnets. A methylene blue leak test is routinely performed, with negative results, this time testing both anastomoses. Finally, the magnet-assisted omega section is made with the retraction of the limb to finish the Roux-en-Y.
Oxycodone is an opioid agonist of the morphine-type. Such drugs are sought by drug abusers and people with addiction disorders and are subject to criminal diversion.

Oxycodone can be abused in a manner similar to other opioid agonists, legal or illicit. This should be considered when prescribing or dispensing Oxycodone HCl Controlled-Release Tablets in situations where the physician or pharmacist is concerned about an increased risk of misuse, abuse, or diversion.

Oxycodone HCl Controlled-Release Tablets have been reported as being abused by crushing, chewing, snorting, or injecting the dissolved product. These practices will result in the uncontrolled delivery of the opioid and pose a significant risk to the abuser that could result in overdose and death (see WARNINGS and DRUG ABUSE AND ADDICTION).

Concerns about abuse, addiction, and diversion should not prevent the proper management of pain. 

Healthcare professionals should contact their State Professional Licensing Board, or State Controlled Substances Authority for information on how to prevent and detect abuse or diversion of this product.
OBJECTIVE: This study was conducted to molecularly identify and classify Cryptosporidium spp. in fecal samples (n=150) from patients with diarrhea received at the microbiology laboratory of a private hospital in Denizli.
METHODS: In this study, the positivity of Cryptosporidium spp. in fecal samples was investigated using direct microscopy, Kinyoun's acid-fast staining method, and Nested polymerase chain reaction (PCR) techniques. Positive PCR products were sequenced.
RESULTS: In the examined fecal samples of patients with diarrhea, no parasites were detected through direct microscopic examination. Using the Kinyoun acid-fast staining method, Cryptosporidium spp. was identified in 2.7% (n=4) of the samples, while Nested PCR detected it in 4.67% (n=7) of the samples. The four positive samples were sequenced using primers that amplify the 18S rRNA gene region. The sequencing results identified the isolates as C. parvum.
CONCLUSION: Cryptosporidiosis is an important public health issue as it is a zoonotic disease caused by the Cryptosporidium parasite that can be transmitted from animals to humans. This study focuses on the molecular characterization of Cryptosporidium species detected in human fecal samples, which is significant for understanding which specific strains or species are involved in human infections. According to the findings, it is recommended that control measures be implemented to reduce the risk of exposure to Cryptosporidium in both humans and animals in Türkiye.
Impact: The permeabilization of the BBB to deliver therapeutics with MR-guided FUS redefines therapeutic strategies as it improves patient outcomes. To ensure the best translation towards clinical treatment, the evaluation of hemodynamic modifications in the CNS is necessary to refine treatment parameters. Methods: MR-guided FUS was applied at 1.5 MHz with a 50 ms burst every 1 s to open the BBB. CBF, BVf and ADC parameters were monitored with MRI. Cavitation was monitored with a PCD during the FUS sequence and classified with the IUD index into three cavitation levels. We distinctly applied the FUS in the cortex or the striatum. After the BBB permeabilization, neuroinflammation markers were quantified longitudinally. Results: The BBB was successfully opened in all animals in this study and only one animal was classified as "hard" and excluded from the rest of the study. 30 min after FUS-induced BBB opening in the cortex, we measured a 54% drop in CBF and a 13% drop in BVf compared to the contralateral side. After permeabilization of the striatum, a 38% drop in CBF and a 15% drop in BVf were measured. CBF values rapidly returned to baseline, and 90 min after BBB opening, no significant differences were observed. We quantified the subsequent neuroinflammation, noting a significant increase in astrocytic recruitment at 2 days and microglial activation at 1 day after FUS. After 7 days, no more inflammation was visible in the brain. Conclusion: FUS-induced BBB opening transiently modifies hemodynamic parameters such as CBF and BVf, suggesting limited nutrients and oxygen supply to the CNS in the hour following the procedure.